Anika Therapeutics Financial Statements (ANIK)
|
|
Report date
|
|
|
11.03.2022 |
16.03.2023 |
31.12.2023 |
15.03.2024 |
26.04.2024 |
|
04.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
147.8 |
156.2 |
166.7 |
166.7 |
166.7 |
|
160.0 |
Operating Income, bln rub |
|
|
-18.5 |
-19.4 |
-25.4 |
-87.6 |
-25.4 |
|
-57.8 |
EBITDA, bln rub |
? |
|
2.62 |
-4.91 |
-18.4 |
2.52 |
-11.2 |
|
-50.6 |
Net profit, bln rub |
? |
|
4.13 |
-14.9 |
-82.7 |
-82.7 |
-82.7 |
|
-64.4 |
|
OCF, bln rub |
? |
|
8.40 |
4.41 |
|
-1.79 |
-1.79 |
|
3.82 |
CAPEX, bln rub |
? |
|
5.14 |
7.49 |
|
5.43 |
5.43 |
|
6.43 |
FCF, bln rub |
? |
|
3.25 |
-3.08 |
|
-7.22 |
-7.22 |
|
-2.61 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
|
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
101.4 |
113.0 |
128.5 |
191.5 |
128.5 |
|
112.7 |
Cost of production, bln rub |
|
|
64.9 |
62.7 |
63.6 |
63.6 |
63.6 |
|
105.1 |
R&D, bln rub |
|
|
27.3 |
28.2 |
32.7 |
32.7 |
32.7 |
|
30.1 |
Interest expenses, bln rub |
|
|
0.000 |
0.654 |
0.000 |
0.000 |
2.31 |
|
0.592 |
|
Assets, bln rub |
|
|
347.5 |
349.1 |
270.6 |
270.6 |
270.6 |
|
231.4 |
Net Assets, bln rub |
? |
|
287.1 |
285.6 |
212.3 |
212.3 |
212.3 |
|
179.9 |
Debt, bln rub |
|
|
19.2 |
30.9 |
26.9 |
29.0 |
29.0 |
|
27.5 |
Cash, bln rub |
|
|
94.4 |
86.3 |
72.9 |
72.9 |
72.9 |
|
62.4 |
Net debt, bln rub |
|
|
-75.1 |
-55.4 |
-46.0 |
-43.8 |
-43.8 |
|
-34.8 |
|
Ordinary share price, rub |
|
|
35.8 |
29.6 |
22.7 |
22.7 |
22.7 |
|
20.0 |
Number of ordinary shares, mln |
|
|
14.4 |
14.6 |
14.7 |
14.7 |
14.7 |
|
14.8 |
|
Market cap, bln rub |
|
|
516 |
431 |
332 |
332 |
332 |
|
295 |
EV, bln rub |
? |
|
441 |
376 |
286 |
288 |
288 |
|
261 |
Book value, bln rub |
|
|
197 |
204 |
205 |
200 |
200 |
|
169 |
|
EPS, rub |
? |
|
0.29 |
-1.02 |
-5.64 |
-5.64 |
-5.64 |
|
-4.36 |
FCF/share, rub |
|
|
0.23 |
-0.21 |
0.00 |
-0.49 |
-0.49 |
|
-0.18 |
BV/share, rub |
|
|
13.7 |
14.0 |
14.0 |
13.7 |
13.7 |
|
11.5 |
|
EBITDA margin, % |
? |
|
1.77% |
-3.14% |
-11.0% |
1.51% |
-6.73% |
|
-31.7% |
Net margin, % |
? |
|
2.80% |
-9.51% |
-49.6% |
-49.6% |
-49.6% |
|
-40.3% |
FCF yield, % |
? |
|
0.63% |
-0.71% |
0.00% |
-2.17% |
-2.17% |
|
-0.88% |
ROE, % |
? |
|
1.44% |
-5.20% |
-38.9% |
-38.9% |
-38.9% |
|
-35.8% |
ROA, % |
? |
|
1.19% |
-4.26% |
-30.5% |
-30.5% |
-30.5% |
|
-27.8% |
|
P/E |
? |
|
124.8 |
-29.0 |
-4.02 |
-4.02 |
-4.02 |
|
-4.58 |
P/FCF |
|
|
158.6 |
-140.1 |
|
-46.0 |
-46.0 |
|
-113.3 |
P/S |
? |
|
3.49 |
2.76 |
1.99 |
1.99 |
1.99 |
|
1.85 |
P/BV |
? |
|
2.62 |
2.12 |
1.62 |
1.66 |
1.66 |
|
1.75 |
EV/EBITDA |
? |
|
168.6 |
-76.4 |
-15.6 |
114.6 |
-25.7 |
|
-5.14 |
Debt/EBITDA |
|
|
-28.7 |
11.3 |
2.50 |
-17.4 |
3.91 |
|
0.69 |
|
R&D/CAPEX, % |
|
|
531.3% |
376.5% |
|
602.4% |
602.4% |
|
467.6% |
|
CAPEX/Revenue, % |
|
|
3.48% |
4.79% |
0.00% |
3.26% |
3.26% |
|
4.02% |
|
Anika Therapeutics shareholders |